Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Stocks

Genmab Stock: Breakthrough Therapy Sparks 5% Surge

Felix Baarz by Felix Baarz
August 7, 2025
in Stocks
0
Genmab Stock
0
SHARES
6
VIEWS
Share on FacebookShare on Twitter

Danish biotech firm Genmab saw its shares jump over 5% to $22.70 after announcing groundbreaking Phase 3 trial results for its lymphoma therapy. The EPCORE FL-1 study showed a 79% reduction in disease progression or death risk for patients with relapsed follicular lymphoma when treated with Epcoritamab combined with Rituximab and Lenalidomide. Both primary endpoints were met, with a remarkable 95.7% response rate. The U.S. FDA has granted accelerated review, with approval expected by November 30, potentially making this the first bispecific antibody combo for second-line treatment of the disease in the U.S.

Financial Momentum and Pipeline Strength

Genmab’s revenue grew 19% to $1.64 billion in H1 2025, driven by blockbuster drugs DARZALEX and Kesimpta. Operating profit nearly doubled to $548 million, prompting raised full-year guidance. Beyond Epcoritamab, the company is advancing Rinatabart sesutecan for endometrial cancer, bolstering its oncology portfolio. A strategic partnership with a major pharma firm enhances global commercialization prospects, positioning Genmab as a key player in innovative cancer therapies.

Ad

Genmab Stock: Buy or Sell?! New Genmab Analysis from February 7 delivers the answer:

The latest Genmab figures speak for themselves: Urgent action needed for Genmab investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Genmab: Buy or sell? Read more here...

Tags: Genmab
Felix Baarz

Felix Baarz

My name is Felix Baarz, and I look back on over fifteen years of experience as a business journalist. I have always been fascinated by the mechanisms and dynamics of global financial markets as well as the complex economic and political interconnections that shape our world. With this passion, I have made a name for myself as an expert on international financial markets and dedicate myself with great commitment to making even the most complex topics understandable and accessible to my readers. My roots lie in Cologne, where I was born and raised. Early on, my curiosity about economic topics and international developments sparked my interest in journalism. After completing my studies, I began my career as a business editor at a respected German trade publication. Here I laid the foundation for my professional career, but my curiosity soon drew me out into the wider world. A turning point in my life was moving to New York, where I lived for six years and gained insight into leading media houses. In this vibrant metropolis, I was able to report firsthand from the heart of the global financial world. From daily developments on Wall Street to major economic policy decisions that make waves worldwide, I had the opportunity to write about central topics that move people and markets alike. This time shaped my perspective and sharpened my view of global interconnections.

Related Posts

Eli Lilly Stock
Stocks

Eli Lilly’s Strategic Diversification Amid Weight-Loss Drug Competition

November 18, 2025
Micron Stock
Stocks

Micron Shares Approach Peak: What Comes After the AI Rally?

November 18, 2025
Varonis Stock
Stocks

Varonis Shares Plunge Amidst Mixed Signals

November 18, 2025
Next Post
Datadog Stock

Datadog Stock: Soars on Strong Earnings and AI Boom

Eli Lilly Stock

Eli Lilly Stock: Surging on Indian Demand and Market Dominance

Yandex Stock

Yandex Stock: Cloud Specialist Nebius Soars on Record Growth

Recommended

ASTeMobile Stock

Regulatory Hurdles Mount for ASTeMobile as T-Mobile Raises Interference Concerns

3 months ago
Pebblebrook Hotel Stock

Pebblebrook Hotel Trust: CEO Share Sale Coincides with Dividend Declaration

2 months ago
U.S. Gold Stock

U.S. Gold Secures Critical Infrastructure Deal for Flagship Project

5 months ago
Kraft Heinz Stock

Kraft Heinz Faces Mounting Challenges as Key Brands Struggle

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Claros Mortgage Trust Secures Financial Flexibility Through Strategic Debt Overhaul

Bar Harbor Bankshares Surpasses Forecasts with Strong Q4 Performance

FRP Holdings: Annual Report to Provide Insight on Key Market Trends

Trending

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce
Newsletter

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

by Stephanie Dugan
February 7, 2026
0

Dear readers, Two hundred billion dollars. That is the figure Amazon CEO Andy Jassy pushed into the...

Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026
Potbelly Stock

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

February 7, 2026
Conduent Stock

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

February 7, 2026
Blue Ridge Bankshares Stock

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce
  • Graftech Shares Plunge on Bleak Quarterly Results
  • Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com